Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Original Article
J.C.-H. Yang, S. Lu, H. Hayashi, E. Felip, A.I. Spira, N. Girard, Y.J. Kim, S.-H. Lee, Y. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E. Korbenfeld, J.M. Dias, B. Besse, A. Passaro, K.-H. Lee, H. Xiong, S.-H. How, Y. Cheng, G.-C. Chang, H. Yoshioka, M. Thomas, D. Nguyen, S.-H.I. Ou, S. Mukhedkar, K. Prabhash, M. D’Arcangelo, J. Alatorre-Alexander, J.C.V. Limón, S. Alves, D. Stroyakovskiy, M. Peregudova, M.A.N. Şendur, O. Yazici, R. Califano, V.G. Calderón, F.d. Marinis, S.-W. Kim, S.M. Gadgeel, S. Owen, J. Xie, T. Sun, J. Mehta, R. Venkatasubramanian, M. Ennis, E. Fennema, M. Daksh, A. Roshak, J. Man, R.E. Knoblauch, J.M. Bauml, M. Baig, S. Shah, S. Sethi, and B.C. Cho
N Engl J Med 2025;393:1681-1693
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation

Facebook
X
LinkedIn
Forward